SG11201507305SA - Pharmaceutical combination drug - Google Patents
Pharmaceutical combination drugInfo
- Publication number
- SG11201507305SA SG11201507305SA SG11201507305SA SG11201507305SA SG11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA SG 11201507305S A SG11201507305S A SG 11201507305SA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical combination
- combination drug
- drug
- pharmaceutical
- combination
- Prior art date
Links
- 229940000425 combination drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130027114 | 2013-03-14 | ||
PCT/KR2014/002178 WO2014142607A1 (en) | 2013-03-14 | 2014-03-14 | Pharmaceutical combination drug |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201507305SA true SG11201507305SA (en) | 2015-10-29 |
Family
ID=51537139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507305SA SG11201507305SA (en) | 2013-03-14 | 2014-03-14 | Pharmaceutical combination drug |
Country Status (16)
Country | Link |
---|---|
US (1) | US9592233B2 (en) |
EP (1) | EP2974719B1 (en) |
JP (1) | JP6068765B2 (en) |
KR (1) | KR101502031B1 (en) |
CN (2) | CN105120845A (en) |
AU (1) | AU2014230182B2 (en) |
CA (1) | CA2905686C (en) |
ES (1) | ES2747098T3 (en) |
MX (1) | MX368148B (en) |
MY (1) | MY174729A (en) |
PH (1) | PH12015502108A1 (en) |
RU (1) | RU2639818C2 (en) |
SA (1) | SA515361123B1 (en) |
SG (1) | SG11201507305SA (en) |
WO (1) | WO2014142607A1 (en) |
ZA (1) | ZA201507576B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101545268B1 (en) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | Tablet and method of preparing the same |
WO2017091041A1 (en) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | Novel salt of fimasartan |
CN105784867B (en) * | 2016-03-28 | 2019-01-01 | 北京睿创康泰医药研究院有限公司 | Make the purposes of reference standard for analyzing HPLC method and these impurity of the Fimasartan in relation to substance |
KR102078691B1 (en) * | 2017-11-30 | 2020-02-19 | 보령제약 주식회사 | Solid dispersion comprising Fimasartan |
KR102201396B1 (en) * | 2017-11-30 | 2021-01-11 | 보령제약 주식회사 | Phamaceutical composition comprising Fimasartan |
KR101997652B1 (en) * | 2018-01-22 | 2019-07-08 | 보령제약 주식회사 | Pharmaceutical formulation |
KR101992400B1 (en) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | Pharmaceutical formulation |
KR102022694B1 (en) * | 2019-02-20 | 2019-09-18 | 주식회사 네비팜 | Pharmaceutical composition |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
CA2537271A1 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
CN101461799B (en) * | 2008-12-31 | 2011-06-29 | 苏州中化药品工业有限公司 | Stable pravastatin medicament composition and preparation method thereof |
ES2364011B1 (en) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
KR101058284B1 (en) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | Novel Process for the Preparation of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide |
CN104610164B (en) | 2010-01-21 | 2018-03-16 | 保宁制药株式会社 | 2 (base of 2 normal-butyl, 4 hydroxyl, 6 methylpyrimidine 5) N, the preparation method of N dimethyl acetamides |
KR20110097168A (en) | 2010-02-24 | 2011-08-31 | 근화제약주식회사 | New pharmaceutical composition for treatment of hyperlipidemia |
KR101248804B1 (en) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN |
CN101972260B (en) * | 2010-11-24 | 2012-05-02 | 天津市汉康医药生物技术有限公司 | Rosuvastatin calcium oral pharmaceutical composition |
CN102485228B (en) * | 2010-12-02 | 2015-06-10 | 鲁南制药集团股份有限公司 | Pharmaceutical composition and purpose thereof |
SG194162A1 (en) * | 2011-04-12 | 2013-11-29 | Boryung Pharm | Antihypertensive pharmaceutical composition |
KR101168136B1 (en) | 2011-08-08 | 2012-07-24 | 보령제약 주식회사 | Antihypertensive pharmaceutical composition |
-
2014
- 2014-03-14 WO PCT/KR2014/002178 patent/WO2014142607A1/en active Application Filing
- 2014-03-14 JP JP2015562935A patent/JP6068765B2/en not_active Expired - Fee Related
- 2014-03-14 US US14/774,927 patent/US9592233B2/en active Active
- 2014-03-14 KR KR1020140030190A patent/KR101502031B1/en active IP Right Grant
- 2014-03-14 AU AU2014230182A patent/AU2014230182B2/en not_active Ceased
- 2014-03-14 ES ES14762250T patent/ES2747098T3/en active Active
- 2014-03-14 CN CN201480015539.2A patent/CN105120845A/en active Pending
- 2014-03-14 CN CN201910375600.9A patent/CN110123771A/en active Pending
- 2014-03-14 MY MYPI2015702913A patent/MY174729A/en unknown
- 2014-03-14 CA CA2905686A patent/CA2905686C/en active Active
- 2014-03-14 MX MX2015011988A patent/MX368148B/en active IP Right Grant
- 2014-03-14 RU RU2015142255A patent/RU2639818C2/en active
- 2014-03-14 SG SG11201507305SA patent/SG11201507305SA/en unknown
- 2014-03-14 EP EP14762250.0A patent/EP2974719B1/en active Active
-
2015
- 2015-09-14 PH PH12015502108A patent/PH12015502108A1/en unknown
- 2015-09-14 SA SA515361123A patent/SA515361123B1/en unknown
- 2015-10-12 ZA ZA2015/07576A patent/ZA201507576B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR101502031B1 (en) | 2015-03-12 |
AU2014230182B2 (en) | 2016-12-22 |
JP2016512234A (en) | 2016-04-25 |
AU2014230182A1 (en) | 2015-09-24 |
MY174729A (en) | 2020-05-11 |
EP2974719B1 (en) | 2019-08-28 |
EP2974719A4 (en) | 2016-08-03 |
EP2974719A1 (en) | 2016-01-20 |
US20160022679A1 (en) | 2016-01-28 |
CN105120845A (en) | 2015-12-02 |
US9592233B2 (en) | 2017-03-14 |
MX2015011988A (en) | 2015-12-01 |
RU2015142255A (en) | 2017-04-26 |
JP6068765B2 (en) | 2017-01-25 |
SA515361123B1 (en) | 2018-04-29 |
CA2905686A1 (en) | 2014-09-18 |
ES2747098T3 (en) | 2020-03-10 |
PH12015502108B1 (en) | 2016-01-18 |
PH12015502108A1 (en) | 2016-01-18 |
ZA201507576B (en) | 2017-01-25 |
MX368148B (en) | 2019-09-20 |
RU2639818C2 (en) | 2017-12-22 |
BR112015022000A8 (en) | 2023-01-17 |
BR112015022000A2 (en) | 2017-07-18 |
WO2014142607A1 (en) | 2014-09-18 |
KR20140113512A (en) | 2014-09-24 |
CN110123771A (en) | 2019-08-16 |
CA2905686C (en) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201905426B (en) | Drug combinations | |
HRP20180684T1 (en) | Drug combination | |
GB201306610D0 (en) | Pharmaceutical compounds | |
ZA201507576B (en) | Pharmaceutical combination drug | |
HK1223833A1 (en) | Pharmaceutical dosage forms | |
ZA201600027B (en) | Pharmaceutical preparation | |
ZA201506465B (en) | Pharmaceutical preparation | |
GB201316662D0 (en) | Pharmaceutical Combination | |
GB201310496D0 (en) | Pharmaceutical combinations | |
GB201301723D0 (en) | Pharmaceutical combinations | |
GB201308780D0 (en) | Pharmaceutical compounds |